Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant‐treated rectal adenocarcinoma

• DOI: 10.1111/his.15192
• Publication Date: 2024-04-17T09:54:26Z
• Authors: Susan Aherne; Mark Donnelly; Éanna J Ryan; Matthew G Davey; Ben Creavin; Erinn McGrath; Aoife McCarthy; Robert Geraghty; David Gibbons; Iris Nagtegaal; Alessandro Lugli; Richard Kirsch; Sean T Martin; Desmond C Winter; Kieran Sheahan
• Keywords: Neoadjuvant Therapy; Tumor budding

Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility TB assessment setting treatment.